Telix applauds NCCN radiotracer update

2021 01 16 00 14 5464 Prostate Cancer 400

Injection kit developer Telix applauded the National Comprehensive Cancer Network's (NCCN) decision to update its guidelines on prostate-specific membrane antigen (PSMA) PET imaging in prostate cancer testing.

The NCCN added gallium-68 (Ga-68) PSMA-11 and F-18 piflufolastat (Pylarify, Lantheus Medical Imaging) to recommendations on the use of radiotracers in prostate cancer testing.

Telix's New Drug Application for investigational imaging product Illuccix, a kit for the preparation of Ga-68 PSMA-11, is in the late stages of review by the U.S. Food and Drug Administration, the company said.

The NCCN update suggests conventional imaging with CT or MRI is not a necessary prerequisite to PSMA-PET and that PSMA-PET/CT or PSMA-PET/MRI can serve as equally effective imaging tools for patients with suspected prostate cancer, Telix said.

NCCN guidelines are a recognized standard for clinical direction and policy in cancer care and are used widely by clinicians and payors.

Page 1 of 593
Next Page